格卡瑞韦/哌仑他韦超短疗程治愈 HCV 感染：病例报告及文献复习。
Glecaprevir/pibrentasvir ultra-short treatment to cure HCV infection: case report and literature review.
机构信息
Department of Public Health and Infectious Diseases, Sapienza University, Rome, Italy.
Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
出版信息
Infez Med. 2020 Dec 1;28(4):616-620.
Shortening therapy duration with direct-acting antiviral agents (DAAs) is desirable to pursue the WHO target of HCV eradication by 2030. We report two cases of HCV-infected women who achieved sustained virologic response after an ultra-short treatment with glecaprevir/pibrentasvir (G/P), discontinued due to cutaneous adverse events, and analyze similar cases reported in the literature. Female gender seems to be a prevailing characteristic in this group of patients. G/P, due to its pangenotypic and strong antiviral activity, may represent a candidate for a shortened DAA regimen in non-cirrhotic treatment-naive subjects.
缩短直接作用抗病毒药物（DAAs）的治疗时间是实现 2030 年世卫组织消除 HCV 目标的理想选择。我们报告了两例 HCV 感染女性患者，她们在因皮肤不良反应而停止使用 glecaprevir/pibrentasvir（G/P）进行超短疗程治疗后实现了持续病毒学应答，并分析了文献中报告的类似病例。女性似乎是这群患者的一个主要特征。G/P 由于其泛基因型和强大的抗病毒活性，可能是无肝硬化初治患者缩短 DAA 方案的候选药物。
Zotero 插件